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Objectives The aim of this study was to evaluate the long-term effects of living-donor lobar lung transplantation (LDLLT) for
critically ill patients with pulmonary arterial hypertension (PAH) who failed in epoprostenol treatment.
Background Although continuous epoprostenol infusion has markedly improved survival in patients with PAH, some patients
do not benefit from this therapy.
Methods From July 1998 to December 2003, 28 consecutive PAH patients who were treated with epoprostenol and ac-
cepted as candidates for lung transplantation were enrolled. All data were prospectively collected. As of July
2006, LDLLT was performed in 11 of those patients whose condition was deteriorating. Cadaveric lung trans-
plantation (CLT) was performed in 2 patients. Medical treatment was continued in 15 patients.
Results There was no mortality in patients receiving LDLLT during a follow-up period of 11 to 66 months (average 48
months), and all patients returned to World Health Organization functional class I. Mean pulmonary artery pressure
decreased from 62  4 mm Hg to 15 2 mm Hg (p  0.001) at discharge and remained normal at 3 years. One
CLT patient died of primary graft failure. Among medically treated patients, 6 patients died of disease progression.
The survival rate was 100% at 5 years for patients receiving LDLLT, and 80% at 1 year, 67% at 3 years, and 53% at
5 years for patients medically treated (p  0.028). All living donors have returned to their previous lifestyles.
Conclusions These follow-up data support the option of LDLLT in patients with PAH who would die soon otherwise. (J Am
Coll Cardiol 2007;50:523–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.054d
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fiulmonary arterial hypertension (PAH) is defined as a
roup of disease characterized by a progressive increase in
ulmonary vascular resistance (1). Epoprostenol, a potent
hort-acting vasodilator and inhibitor of platelet aggrega-
ion, was a therapeutic breakthrough. In long-term
ollow-up studies of patients with idiopathic pulmonary
rterial hypertension (IPAH) receiving epoprostenol intra-
enous therapy, the 3-year survival ranged from 62% to 88%
2–5). The survival rate after lung transplantation was
eported to be rather worse than that of patients receiving
poprostenol treatment (6). Living-donor lobar lung trans-
lantation (LDLLT) has become an established strategy to
rom the Departments of *Cancer and Thoracic Surgery, †Cardiovascular Medicine,
Anesthesiology and Resuscitology, and §Cardiovascular Surgery, Okayama Univer-
ity Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama,
apan. This work was supported by a Grant for Development of Advanced Medicine
n Lung Transplantation from the Ministry of Health, Labor, and Welfare, Japan.n
Manuscript received January 2, 2007; revised manuscript received March 5, 2007,
ccepted March 15, 2007.eal with the shortage of cadaveric donors (7,8). The aim of
his study was to evaluate the long-term effects of LDLLT
or critically ill patients with PAH who failed in epoproste-
ol treatment.
ethods
his study included all 28 PAH (clinically diagnosed with
PAH or familial PAH) patients on epoprostenol therapy
onsecutively accepted as lung transplant candidates at
kayama University Hospital between July 1998 and De-
ember 2003. The lung transplant program was approved by
he Ethics Committee at Okayama University Medical
chool. Written informed consent was obtained from all
atients. The diagnosis of IPAH was established according
o standard diagnostic criteria (9). Although all patients had
nitial diagnosis of IPAH or familial PAH, pathological
ndings revealed other causes of PAH in some patients as
oted in the Results section. Indications for lung transplan-
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Organization (WHO) functional
class III/IV despite optimum
medical therapy and mean pul-
monary artery pressure 50 mm
Hg (10).
Medical treatment. Epoproste-
nol therapy was initiated at a dose
of 0.5 to 1.0 ng/kg/min, and the
dose was increased up to 10 to 15
ng/kg/min at discharge. After dis-
charge, the epoprostenol dose was
initially increased weekly by 0.5
to 1.0 ng/kg/min. Dose adjust-
ments of epoprostenol were based
on clinical symptoms consistent
with clinical deterioration or the
occurrence of adverse effects, dis-
tance walked during exercise
testing, and hemodynamic mea-
surements. Patients on the wait-
ng list for transplantation continued to receive maximum
edical treatment including the oral dual endothelin recep-
or antagonist bosentan, which became available in June
005.
adaveric lung transplantation (CLT). Conventional bi-
ateral lung transplantation was performed under cardio-
ulmonary bypass when a cadaveric donor became
vailable.
DLLT. The policy of our program has been to limit
DLLT to critically ill patients. Right and left lower
obes from 2 healthy donors were implanted under
ardiopulmonary bypass in the recipient. Relatives within
he second degree or spouses have been the only donors
sed at our institution. When the total forced lung
apacity (FVC) of the 2 grafts was 50% of the predicted
VC of the recipient, we accepted the size disparity (11).
Abbreviations
and Acronyms
BOS  bronchiolitis
obliterans syndrome
CLT  cadaveric lung
transplantation
FVC  forced vital capacity
IPAH  idiopathic
pulmonary arterial
hypertension
LDLLT  living-donor lobar
lung transplantation
PAH  pulmonary arterial
hypertension
PCH  pulmonary capillary
hemangiomatosis
PVOD  pulmonary veno-
occlusive disease
WHO  World Health
Organization
aseline Clinical Characteristics of 28 PAH Patients When Accept
Table 1 Baseline Clinical Characteristics of 28 PAH Patients W
All Patients
(n  28)
Medical Treatment
(n  15)
Women/men 20/8 10/5
Age (yrs) 24.4 1.6 26.9 2.1
Hemodynamics
CI (l/min/m2) 2.4 0.1 2.6 1.6
PVR (dyn·s·cm5) 1,509 117 1,366 150
mPAP (mm Hg) 61 2 59 3
mPCWP (mm Hg) 8.2 0.6 8.3 1.0
mRAP (mm Hg) 7.1 0.7 6.6 1.1
WHO functional class III/IV 18/10 11/4
Epoprostenol
Duration (days) 340 79 256 104
Dose (ng/kg/min) 38 7 25 7
Inotropes / 12/16 5/10I cardiac index; CLT cadaveric lung transplantation; LDLLT living-donor lobar lung transplantation;
RAP  mean right atrial pressure; PAH  pulmonary arterial hypertension; PVR  pulmonary vascularPostoperative immunosuppression consisted of triple-
rug therapy under a previously described protocol (8).
outine full postoperative assessment was performed before
ischarge, at 6 months, 12 months, and then annually.
ight heart catheterization was performed before discharge,
t 12 months, and 36 months.
nalysis of data. All data were collected prospectively.
hree groups, patients who remained in medical treat-
ent, patients who received CLT, and patients who
eceived LDLLT, were compared in this study. Because
LT was performed in only 2 patients, statistical analysis
as performed between the medical treatment and
DLLT groups.
All values are given as mean  standard error of the
ean. Baseline comparisons were performed using the
earson chi-square test (gender, inotropes), Kruskal-
allis analysis of variance (WHO functional class), and
nalysis of variance (all others). Effects of LDLLT were
nalyzed using univariate and multivariate repeated mea-
ure of analysis. Observed survival data were reported as
aplan-Meier estimates; the log-rank test was used to
xplore the significance of the difference between the
roups. Comparisons of latest WHO functional class
ere performed using Kruskal-Wallis analysis of vari-
nce. Differences were considered significant at a proba-
ility value of 0.05.
esults
s of July 2006, CLT was performed in 2 patients, LDLLT
as performed in 11 patients, and medical treatment was
ontinued in 15 patients.
The 28 patients’ clinical characteristics when they were
ccepted as lung transplant candidates are shown in Table 1.
wenty-five patients (89.3%) were clinically diagnosed with
PAH. Three patients (10.7%), 1 in the CLT group and 2 in the
edical treatment group, were identified as having familial PAH.
Lung Transplant Candidates
Accepted as Lung Transplant Candidates
LDLLT
(n  11)
CLT
(n  2)
p Value
Medical Treatment vs. LDLLT
9/2 1/1 0.549
22.4 3.2 17.5 1.5 0.239
2.1 0.2 2.9 0.3 0.051
1,782 229 1,146 33 0.135
62 4 67 4 0.546
7.6 0.9 10.0 1.0 0.629
8.4 1.1 4.0 0.0 0.290
5/6 2/0 0.199
504 154 72 12 0.17
61 14 10 2 0.016
7/4 0/2 0.136ed as
henmPAPmean pulmonary artery pressure; mPCWPmean pulmonary capillary wedge pressure;
resistance; WHO  World Health Organization.
d
p
w
M
i
A
d
g
d
f
f
o
C
t
T
L
r
l
f
r
W
l
L
w
t
m
t
L
r
d
i
r
e
t
D
d
w
w
9
p
n
c
m
p
(
c
d
se
lin
e
C
ha
ra
ct
er
is
ti
cs
of
th
e
1
1
P
at
ie
nt
s
R
ec
ei
vi
ng
LD
LL
T
at
th
e
Ti
m
e
of
Tr
an
sp
la
nt
at
io
n
ab
le
2
B
as
el
in
e
C
ha
ra
ct
er
is
ti
cs
of
th
e
1
1
P
at
ie
nt
s
R
ec
ei
vi
ng
LD
LL
T
at
th
e
Ti
m
e
of
Tr
an
sp
la
nt
at
io
n
at
ie
nt
N
o.
A
ge
(y
rs
)/
G
en
de
r
H
ei
gh
t
(c
m
)
W
ei
gh
t
(k
g)
C
I
(l
/
m
in
/
m
2
)
P
V
R
(d
yn
·s
·c
m

5
)
m
P
A
P
(m
m
H
g)
m
P
C
W
P
(m
m
H
g)
m
R
A
P
(m
m
H
g)
W
H
O
C
la
ss
Ep
op
re
st
en
ol
In
ot
ro
pe
s
D
ur
at
io
n
D
os
e
1
1
9
/F
1
5
7
3
8
.0
1
.4
2
,0
1
2
5
8
1
1
1
5
IV
1
,7
2
6
1
6
0

2
1
0
/M
1
2
2
2
0
.4
2
.7
1
,7
7
2
5
9
8
9
III
7
3
7
9
0

3
2
7
/F
1
6
0
5
0
.8
1
.5
—
5
3
—
1
0
IV
8
4
0
2
4

4
8
/M
1
2
6
2
0
.0
1
.7
2
,3
4
0
5
2
1
0
5
IV
2
8
1
1
2
3

5
1
3
/F
1
4
7
3
9
.7
2
.2
3
,2
8
2
9
8
6
4
IV
5
7
0
9
0

6
3
1
/F
1
6
0
4
1
.7
2
.1
1
,2
2
9
4
8
6
8
IV
8
8
1
4
0

7
1
3
/F
1
4
8
3
5
.0
1
.7
2
,2
7
7
6
7
8
6
IV
3
0
9
7
6

8
2
5
/F
1
6
4
4
5
.0
1
.9
1
,4
5
5
5
5
4
8
IV
1
,3
4
4
5
0

9
2
8
/F
1
5
2
3
3
.0
1
.8
2
,2
7
8
6
6
3
1
0
III
1
1
5
4
6

1
0
4
3
/F
1
5
6
5
2
.8
2
.5
1
,2
2
9
7
2
1
2
1
5
IV
3
5
0
5
0

1
1
3
5
/F
1
6
0
5
4
.0
3
.1
6
4
1
5
1
1
0
9
IV
1
,2
1
0
1
2
7

M
ea
n
2
2
.9

3
.4
1
5
0

4
3
9
.1

3
.5
2
.1

0
.2
1
,8
5
2

2
2
5
6
2

4
7
.8

0
.9
9
.0

1
.1
6
8
8

1
6
3
8
9

1
3
re
vi
at
io
ns
as
in
Ta
bl
e
1
.
525JACC Vol. 50, No. 6, 2007 Date et al.
August 7, 2007:523–7 Living-Donor Lobar Lung Transplantation for PAHCardiac index was marginally lower (p  0.051), and the
ose of epoprostenol was significantly higher (p  0.016) in
atients who subsequently received LDLLT than in those
ho remained in medical treatment.
edical treatment. Among the 15 patients who remained
n medical treatment, 6 patients died of disease progression.
utopsy was performed in 4 patients. Two patients were
iagnosed with IPAH, 1 with pulmonary capillary heman-
iomatosis (PCH), and 1 with pulmonary veno-occlusive
isease (PVOD).
Among the 9 survivors, 8 patients recovered to WHO
unctional class II and they were removed from the active list
or lung transplantation. Six of them are currently treated with
ral bosentan along with intravenous epoprostenol.
LT. Two patients received conventional bilateral lung
ransplantation. One patient died of primary graft failure.
he other patient is alive after 34 months.
DLLT. Eleven patients received LDLLT. Seven patients
eceived LDLLT within 2 weeks after being accepted as
ung transplant candidates. Four patients waited on the list
or cadaveric donors for 80 to 1,244 days, and then they
eceived LDLLT due to their clinical deterioration from
HO functional class III to class IV or due to episodes of
ife-threatening events such as massive hemoptysis.
The 11 patients’ clinical characteristics when they received
DLLT are shown in Table 2. Two patients (cases 3 and 7)
ere too sick to undergo right heart catheterization before
ransplantation, so pulmonary hemodynamics measured 12
onths before transplant were used as preoperative data.
One pediatric patient (case 2) underwent right single lobe
ransplantation (12). The other 10 patients received bilateral
DLLT. The total FVC of the grafts was estimated to
ange from 51.4% to 103.0% (average 70.1%) of the pre-
icted FVC of the recipient.
The major operative morbidity included lung edema requir-
ng reintubation (n  3), bleeding from the chest wall
equiring rethoracotomy (n 2), massive hemoptysis requiring
xtracorporeal membrane oxygenation (n 1), and kinking of
he left pulmonary artery requiring vascular repair (n  1).
uration of mechanical ventilation required was 13.4  3.6
ays, and hospital stay was 75.8  7.9 days. All 11 patients
ere discharged without oxygen inhalation therapy. There
ere no postoperative complications among 21 living donors.
Pathologic diagnoses of the excised lungs were IPAH in
patients, PCH in 1 patient (case 8), and PVOD in 1
atient (case 9).
Functional assessment is summarized in Table 3. Pulmo-
ary hemodynamics improved dramatically at discharge and
ontinued to be excellent at 3 years. Spirometric measure-
ents improved gradually during the first year and exceeded
reoperative values at 1 to 3 years.
Although unilateral bronchiolitis obliterans syndrome
BOS) developed in 2 pediatric recipients (cases 4 and 7), their
ontralateral graft was unaffected. All 11 recipients and 21
onors remained alive during the observation period. Ba T
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Living-Donor Lobar Lung Transplantation for PAH August 7, 2007:523–7omparison in survival and latest function. At the time
f final data analysis in July 2006, the mean time from the
ate the patient was accepted as a lung transplant candidate
o final analysis for all 28 patients was 58 months (range 31
o 95 months). The mean time from LDLLT to final
nalysis was 48 months (range 11 to 66 months). The
urvival rate was 100% at 5 years for patients receiving
DLLT, whereas it was 80% at 1 year, 67% at 3 years, and
3% at 5 years for patients who remained in medical
reatment (Fig. 1) (p  0.028).
The latest patient WHO functional class is summarized
n Table 4. All 11 patients receiving LDLLT are currently
n class I. The functional class was significantly better in
Functional Assessment Before and After LDLLT
Table 3 Functional Assessment Before and
Pretransplant (n  11) 2–3
CI (l/min/m2) 2.1 0.1
PVR (dyn·s·cm5) 1,852 225
mPAP (mm Hg ) 62 4
mPCWP (mm Hg) 7.8 0.9
mRAP (mm Hg) 9.0 1.1
FVC (ml) 2,014 185
%FVC (%) 72.9 5.3
FEV1.0 (ml) 1,517 135
FEV1.0% (%) 76.0 2.4
PaO2 (mm Hg)
PaCO2 (mm Hg) 33.7 1.8
6-min walk (m)
*p  0.05 (vs. pretransplant); †p  0.001 (vs. pretransplant); ‡p  0
to 3 months).
FEV1.0  forced expiratory volume in 1 s; FVC  forced vital capaci
other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Survival Curves in PAH Patients
Survival was assessed from the date of operation in patients receiving transplanta
medically. The survival was significantly better in patients receiving living-donor lob
test. CLT  cadaveric lung transplantation; PAH  pulmonary arterial hypertensionatients receiving LDLLT than in patients who remained
n medical treatment (p  0.001).
iscussion
everal series have demonstrated the positive impact of
poprostenol on survival in IPAH (2–5). There are now 3
lasses of medications that have shown efficacy in the treatment
f PAH: prostanoids (2–5), endothelin receptor antagonists
13), and phosphodiesterase-5 inhibitors (14). Because of the
emarkable improvements of medical treatment for PAH
uring the past decade, determining the indications and timing
or transplantation as a PAH treatment is a difficult challenge
LDLLT
Post-Transplant Interval
s (n  11) 1 Year (n  10) 3 Years (n  9)
 0.2 3.3 0.3* 3.1 0.2†
 27‡ 174 23‡ 172 24‡
 2‡ 16 1‡ 15 1‡
 0.8 6.0 0.6 7.5 1.0
 0.7 1.5 0.6 2.0 0.4
 100 2,073 131§ 2,291 157§
 3.3 78.0 3.0§ 81.3 3.9
 120 1,818 134§ 1,902 141§
 2.3 87.2 1.8 82.7 2.2
 2.1 100.6 3.5 97.0 3.0
 0.6 35.7 0.8 35.5 1.7
 20 457 16§ 518 60§
vs. pretransplant); §p  0.0001 (vs. 2 to 3 months); p  0.01 (vs. 2
2  arterial carbon dioxide tension; PaO2  arterial oxygen tension;
nd from the date of acceptance as lung transplant candidates in patients treated
g transplantation (LDLLT) than in patients medically treated. p  0.028, log-rankAfter
Month
2.8
234
15
5.3
0.5
1,401
57.9
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93.6
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August 7, 2007:523–7 Living-Donor Lobar Lung Transplantation for PAHnowing that the survival after CLT was reported to be rather
orse than epoprostenol treatment (6).
Living-donor lobar lung transplantation was pioneered by
he University of Southern California group. They originally
pplied this procedure almost exclusively to cystic fibrosis
atients and then expanded the indications to other diagnoses
ncluding pediatric IPAH in 5 patients (7). Since January 2000,
e have applied this procedure to both pediatric (12) and adult
15) patients with IPAH. Because LDLLT subjects healthy
onors to a lower lobectomy procedure associated with poten-
ially serious complications, we have accepted only critically ill
PAH patients who failed in epoprostenol therapy.
There were obvious concerns regarding whether pulmonary
ypertension would develop in only 2 lobes implanted. Their
ean pulmonary artery pressure decreased from 62  4 mm
g to 15  2 mm Hg at discharge, validating the functional
apacity of the 2 lobes to handle the entire cardiac output.
The major limitation to long-term survival in CLT is death
ue to chronic rejection (6). In our entire experience of
DLLT in 39 patients with various lung diseases, 8 patients
21%) developed BOS. Interestingly, 7 of 8 patients had
nilateral BOS. The different antigenicity between 2 LDLLT
rafts might explain this phenomenon. Thirty-seven of the 39
DLLT patients (95%) are currently alive.
In the new classification of pulmonary hypertension (1),
CH and PVOD are included in a subgroup termed “PAH
ssociated with significant venous or capillary involvement.”
heir clinical presentation is generally similar to that of
PAH; however, the prognosis seems worse. Of note was
hat both PCH and PVOD were found in patients receiving
DLLT and also in patients on epoprostenol therapy who
ied while on the waiting list.
Although all data were collected prospectively, the major
imitation of this study is its nonrandomized design. Never-
heless, this study suggests that LDLLT can provide better
urvival than medical treatment including epoprostenol. Pa-
ients receiving LDLLT seemed to have more advanced
isease than patients who remained in medical treatment when
hey were accepted as lung transplant candidates (Table 1). All
1 patients receiving LDLLT are currently in class I during the
atest WHO Functional Class
Table 4 Latest WHO Functional Class
Latest WHO
Functional Class
Medical Treatment
(n  15)
LDLLT
(n  11)
CLT
(n  2)
Class I 0 11 1
Class II 8 0 0
Class III 1 0 0
Class IV 0 0 0
Deceased 6 0 1
 0.001 (medical treatment vs. LDLLT) by Kruskal-Wallis analysis of variance.
Abbreviations as in Table 1.ean follow-up period of 48 months (Table 4).It should be also noted that 8 of 15 patients in the
edical treatment group had a long-lasting benefit from
poprostenol therapy and may never require lung transplan-
ation. Although knowledge of predictors of survival in
atients with PAH is helpful, ultimately the timetable must
e set by the unique situation of each patient. These
ollow-up data support the option of LDLLT in patients
ith PAH who would die soon otherwise.
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